Key Takeaways
- • Akin Gump advised Pharmakon Advisors and BioPharma Credit funds on a $200 million five-year term loan facility for Kestra Medical Technologies, with $75 million funded at closing, representing significant non-dilutive debt capital for the wearable medical device sector.
- • The facility structure provides staged funding availability, allowing Kestra to access additional capital beyond the initial tranche while preserving equity ownership—a strategic advantage for life sciences companies navigating product development and commercialization cycles.
- • Pharmakon Advisors and the BioPharma Credit funds secured exposure to a leader in the high-growth wearable medical device and digital healthcare market, positioning the credit investors in a sector with substantial secular tailwinds.
- • The transaction demonstrates institutional appetite for specialized life sciences debt financing, with a 12-lawyer team spanning tax, international trade, healthcare, and corporate expertise—reflecting the regulatory and structural complexity of non-dilutive financing in medtech.
Summary
Akin Gump Strauss Hauer & Feld LLP advised Pharmakon Advisors, LP and the BioPharma Credit funds in closing a $200 million five-year senior secured term loan facility for Kestra Medical Technologies, Ltd., a developer of wearable medical devices and digital healthcare solutions. The transaction closed with an initial $75 million tranche funded at closing, with the remaining $125 million available to Kestra under an accordion structure—providing the company with staged access to capital as business milestones and operational needs evolve.
The financing vehicle underscores the growing importance of non-dilutive debt capital in life sciences funding ecosystems. Rather than raising capital through equity offerings that would dilute existing shareholders, Kestra secured structured borrowing that allows the company to fund product development, regulatory approvals, and commercial expansion while maintaining founder and investor ownership positions. Pharmakon Advisors, a specialist in life sciences credit, led the investment alongside the BioPharma Credit funds—vehicles with deep sector expertise and patient capital structures aligned to medtech development timelines.
The Akin team assembled to execute the transaction included 12 professionals across multiple practice areas, reflecting the deal's complexity. Geoffrey Secol, a tax partner, led the engagement alongside fellow tax partners Stuart Leblang, David Snyder, and Ryan Katz, with senior counsel Miriam Foley and associates Joshua Elkouby and John Kwack providing support. International trade partner Nnedinma Ifudu Nweke, healthcare & life sciences partner Nate Brown, senior counsel Jo-Ellyn Klein, and associate Jenna Becker rounded out the team, alongside corporate associates Casey Braden and Yossi Abadi. The multi-disciplinary team composition reflects standard practice for cross-border medtech financing, requiring expertise in regulatory compliance, transfer pricing, trade considerations, and healthcare reimbursement frameworks.
The transaction signals sustained institutional confidence in wearable medical device companies and digital health platforms, segments experiencing accelerating adoption driven by remote patient monitoring, chronic disease management, and value-based care incentives. For credit investors, the facility offers exposure to an established player in high-growth market segments while maintaining security through asset-backed structures typical of medtech financing.
The financing vehicle underscores the growing importance of non-dilutive debt capital in life sciences funding ecosystems. Rather than raising capital through equity offerings that would dilute existing shareholders, Kestra secured structured borrowing that allows the company to fund product development, regulatory approvals, and commercial expansion while maintaining founder and investor ownership positions. Pharmakon Advisors, a specialist in life sciences credit, led the investment alongside the BioPharma Credit funds—vehicles with deep sector expertise and patient capital structures aligned to medtech development timelines.
The Akin team assembled to execute the transaction included 12 professionals across multiple practice areas, reflecting the deal's complexity. Geoffrey Secol, a tax partner, led the engagement alongside fellow tax partners Stuart Leblang, David Snyder, and Ryan Katz, with senior counsel Miriam Foley and associates Joshua Elkouby and John Kwack providing support. International trade partner Nnedinma Ifudu Nweke, healthcare & life sciences partner Nate Brown, senior counsel Jo-Ellyn Klein, and associate Jenna Becker rounded out the team, alongside corporate associates Casey Braden and Yossi Abadi. The multi-disciplinary team composition reflects standard practice for cross-border medtech financing, requiring expertise in regulatory compliance, transfer pricing, trade considerations, and healthcare reimbursement frameworks.
The transaction signals sustained institutional confidence in wearable medical device companies and digital health platforms, segments experiencing accelerating adoption driven by remote patient monitoring, chronic disease management, and value-based care incentives. For credit investors, the facility offers exposure to an established player in high-growth market segments while maintaining security through asset-backed structures typical of medtech financing.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.